Navigation Links
Takeda Receives New Information on Alogliptin (SYR-322) NDA
Date:3/6/2009

OSAKA, Japan, March 6 /PRNewswire/ -- Takeda Pharmaceutical Company Limited today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, was informed as part of regular discussions about the alogliptin New Drug Application (NDA) with the United States Food and Drug Administration (FDA), that although the alogliptin NDA was filed prior to issuance of FDA's December 2008 guidance on new Type 2 diabetes treatments, the FDA will apply these guidelines when reviewing the alogliptin NDA.

Additionally, the FDA does not believe that the amount of existing alogliptin clinical data is sufficient to meet certain statistical requirements in the new guidance. The agency is open to discussions regarding the design of additional CV studies with alogliptin. Alogliptin's Prescription Drug User Fee Act (PDUFA) date - June 26, 2009 - remains unchanged.

In December, 2008 the FDA issued "Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes".

In October 2008, Takeda received notification from the FDA that it was unable to complete its review of the alogliptin NDA by the original PDUFA date -- October 27, 2008 -- due to internal resource constraints. The FDA did not raise any issues with the data in the alogliptin NDA at that time. In December 2007, Takeda submitted its NDA for alogliptin to the FDA.

Alogliptin, which was discovered by Takeda's wholly owned U.S. subsidiary, Takeda San Diego, Inc. is a dipeptidyl peptidase IV (DPP-4) inhibitor being reviewed as an adjunct to diet and exercise for the treatment of type 2 diabetes.

About DPP-4 Inhibitors

DPP-4 inhibitors inhibit the enzyme dipeptidyl peptidase IV (DPP-4), which metabolizes the insulin-increasing hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). By maintaining the blood levels of GLP-1 and GIP, DPP-4 inhibitors are a newer type of oral anti-diabetic with a novel mechanism of action for lowering blood sugar levels.

GLP-1 and GIP are secreted by the digestive tract following food intake, and stimulate the beta cells in the pancreas--thereby stimulating increased insulin secretion--and it has the potential to improve pancreatic beta-cell function. Furthermore, it is known that because GLP-1 suppresses glucagon secretion from the pancreas, the production of sugar in liver cells is also suppressed.

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda (TSE:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
2. Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
3. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
4. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
5. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
6. Takeda Completes Acquisition of Millennium
7. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
8. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
9. Takeda Announces New U.S. Leadership
10. Takeda submits new drug application for alogliptin (syr-322) in the US
11. Chemizon Announces Research Collaboration Expansion With Takeda
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology: